Address |
PMO Hanzomon, 11/F Tokyo Tokyo 102 Japan |
Employees | - |
Website | http://www.sosei.com |
Updated | 07/08/2019 |
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its proprietary StaR (Stabilised Receptor) technology and structure-based drug design (SBDD) platform enables development of drugs for highly validated, yet historically undruggable or challenging GPCRs. The company has multiple programs targeting Alzheimer's disease, schizophrenia, immuno-oncology, migraine, metabolic disease and other rare and specialty indications. |